Results 111 to 120 of about 589,804 (355)

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Blood Cancer Journal, 2019
Interim analyses of a phase I study with GSK2857916, an antibody–drug conjugate against B cell maturation antigen, have previously reported a 60% overall response and 7.9 months progression-free survival in relapsed/refractory multiple myeloma (MM).
S. Trudel, N. Lendvai, R. Popat, P. Voorhees, B. Reeves, E. Libby, P. Richardson, A. Hoos, I. Gupta, V. Bragulat, Zangdong He, J. Opalinska, A. Cohen   +12 more
semanticscholar   +1 more source

Intracellular trafficking and cellular uptake mechanism of PHBV nanoparticles for targeted delivery in epithelial cell lines [PDF]

, 2017
Indexación: Web of Science; Scopus; Scielo.Background: Nanotechnology is a science that involves imaging, measurement, modeling and a manipulation of matter at the nanometric scale.
Cabana-Brunod, M, Fuentes, JA, Gonzalez-Nilo, FD, Llancalahuen, FM, Maldonado-Biermann, F, Marquez-Miranda, V, Otero, C, Penaloza, JP, Reyes-Ramirez, R, Rodriguez-Diaz, M, Velasquez, LA, Vilos, C   +11 more
core   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Cancers
Simple Summary Since the first antibody–drug conjugate (ADC) was approved in 2000, the landscape of these targeted drugs has evolved over the years, profoundly changing the treatment scenario of various advanced-stage cancers, including solid tumors ...
Virginia Metrangolo, L. Engelholm
semanticscholar   +1 more source

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

EMBO Molecular Medicine, 2020
Despite impressive clinical benefit obtained with anti‐HER2‐targeted therapies, in advances stages, especially in the metastatic setting, HER2‐positive tumors remain incurable. Therefore, it is important to develop novel strategies to fight these tumors,
Lucía Gandullo-Sánchez, E. Capone, A. Ocaña, S. Iacobelli, G. Sala, A. Pandiella   +5 more
semanticscholar   +1 more source

A proanthocyanidin from cinnamomum zeylanicum stimulates phosphorylation of insulin receptor in 3t3-l1 adipocytes [PDF]

, 2006
Non-insulin-dependent diabetes mellitus is due to in large part to insulin resistance, a state where the target cells are no longer responding to ordinary levels of circulating insulin.
Abdul Majid, Fadzilah Adibah, Sarmidi, Mohamad Roji, Taher, Muhammad   +2 more
core   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles [PDF]

, 2010
PEGylated gold nanoparticles are decorated with various amounts of human transferrin (Tf) to give a series of Tf-targeted particles with near-constant size and electrokinetic potential.
C. A. Alabi, C. H. J. Choi, Danscher, Davis, Dreher, Farokhzad, Gatter, Hu-Lieskovan, Ishida, Jiang, Kirpotin, Lopes de Menezes, M. E. Davis, Matsumura, Montet, P. Webster, Park, Perrault, Popielarski, Sawyer, Schmidt, Stein, Zhou   +22 more
core   +2 more sources

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy

Cancer Gene Therapy, 2020
Neuroendocrine (NE) tumors include a diverse spectrum of hormone-secreting neoplasms that arise from the endocrine and nervous systems. Current chemo- and radio-therapies have marginal curative benefits.
Yingnan Si, Seulhee Kim, Jianfa Ou, Yun Lu, Patrick Ernst, Kai Chen, J. Whitt, A. Carter, J. Markert, J. Bibb, Herbert Chen, Lufang Zhou, R. Jaskula-Sztul, X. Liu   +13 more
semanticscholar   +1 more source